HYAL1 and Sepsis: Experimental glycocalyx protectants (e.g., sucrose octasulfate, anti-HYAL1 antibodies) mitigate AKI in sepsis models but have yet to enter clinical translation (Xing et al., 2023; Zhang D. et al., 2020; Yu et al., 2019).